Sign In
News Digest /
StockInvest.us
Author: StockInvest.us
08:06am, Thursday, May 15, 2025
Company Overview: Invivyd, Inc. (NASDAQ: IVVD) is focused on developing monoclonal antibodies (mAbs) for serious viral infectious diseases, primarily COVID-19 through its product PEMGARDA™ (pemivibart).
Key Financial Highlights:
Revenue: Product revenue for Q1 2025 reached $11.3 million, marking...
08:05am, Thursday, May 15, 2025
Venus Concept Inc. (NASDAQ: VERO) Q1 2025 Earnings Overview
Key Financial Metrics:
Total Revenue: $13.6 million (down 21.9% from $17.5 million in Q1 2024)
Net Loss: $(12.4) million (increased from $(9.8) million in Q1 2024)
Cash and Cash Equivalents: $3.2 million (decreased from $4.3 million at ...
08:05am, Thursday, May 15, 2025
**Zenas BioPharma, Inc. (NASDAQ: ZBIO) Overview**
Financial Highlights (3 months ended March 31, 2025):
Total Revenue: $10.0 million (up from $0 in the same period last year)
Net Loss: $33.6 million (compared to $27.8 million loss in Q1 2024)
Operating Expenses: $47.3 million (compared to $27.6 ...
08:04am, Thursday, May 15, 2025
DT Cloud Acquisition Corporation (NASDAQ: DYCQ) is a blank check company incorporated in the Cayman Islands. As of March 31, 2025, the company has not commenced any operations outside its initial public offering (IPO) and the search for potential business combinations.
Key aspects from the latest...
08:04am, Thursday, May 15, 2025
FitLife Brands, Inc. (OTCMKTS: FTLF) has released its quarterly report for Q1 2025. Here are the key points and statistics from the income statement and operations:
Revenue: Decreased 4% year-over-year to $15,936, compared to $16,549 in Q1 2024.
Cost of Goods Sold: Decreased 2% to $9,062 from $9...
08:04am, Thursday, May 15, 2025
Incannex Healthcare Inc. (NASDAQ: IXHL) has released its latest quarterly financial report for the period ending March 31, 2025. Here are some crucial insights into its income statement and current company status:
Key Financial Highlights:
Net Loss: $15.3 million for the nine months ending March...
08:03am, Thursday, May 15, 2025
Company Overview
Precision BioSciences, Inc. (NASDAQ: DTIL) is a clinical stage gene editing company that is focused on developing transformative in vivo therapies using its proprietary ARCUS genome editing platform. The company is currently advancing several gene editing programs targeting rare ...
08:02am, Thursday, May 15, 2025
Abeona Therapeutics Inc. (NASDAQ: ABEO) has reported its financial results for the quarter ended March 31, 2025, with significant developments impacting its financial health and operational outlook.
Key Highlights:
FDA Approval: The company received FDA approval for ZEVASKYN™, the first autologo...
08:02am, Thursday, May 15, 2025
Company Overview
Pyxis Oncology, Inc. (NASDAQ: PYXS) is a Delaware-based clinical stage oncology company focused on developing novel therapeutics for treating solid tumors, particularly head and neck squamous cell carcinoma (HNSCC).
Recent Financial Performance
Net Loss: $21.2 million for Q1 202...
08:02am, Thursday, May 15, 2025
Palvella Therapeutics, Inc. (OTCMKTS: PIRS) has released its quarterly financial results for the period ending March 31, 2025. The firm has undergone significant changes and is focusing on developing therapies for rare genetic skin diseases.
Key Highlights:
Net loss for Q1 2025: $8.2 million, up...
08:01am, Thursday, May 15, 2025
Company Overview
Galectin Therapeutics Inc. (NASDAQ: GALT) is a clinical stage biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer using its expertise in galectin research. The company's lead product candidate, belapectin, is being studied for treatment in p...
08:01am, Thursday, May 15, 2025
Aclarion, Inc. (NASDAQ: ACON)
Aclarion, Inc. has reported its financial results for the first quarter of 2025, revealing both positive growth and challenges. The company specializes in healthcare technology, particularly leveraging magnetic resonance spectroscopy to enhance clinical treatments.
K...
08:00am, Thursday, May 15, 2025
TriSalus Life Sciences, Inc. (NASDAQ: MTAC) is navigating significant developments and challenges as it reports its financial performance for the first quarter of 2025. The company has undergone a recent merger and is dedicated to oncology-focused medical technologies, particularly for solid tumo...
07:04am, Thursday, May 15, 2025
Journey Medical Corporation (NASDAQ: DERM) has released its quarterly financial results for Q1 2025, which have brought both optimistic and challenging aspects to light.
Positive Aspects:
Revenue for Q1 2025 was $13.1 million, a slight increase from $13.0 million in Q1 2024, indicating stable sa...
07:03am, Thursday, May 15, 2025
Nuvera Communications, Inc. (PINK: NUVR)
In the first quarter of 2025, Nuvera Communications, Inc. reported notable changes in its financial performance compared to the same period in 2024. The total operating revenues increased by approximately 5.52% to $17.88 million, driven primarily by growth...
